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Summary The multidrug resistance (MDR) phenotype is presumed to be mostly dependent on changes in the
resistant cell plasma membrane, notably the emergence of a 170 kDa glycoprotein called P-glycoprotein, which
facilitate increased drug efflux. We have previously demonstrated that ATP-enhanced binding of vincristine
(VCR) to plasma membrane vesicles is much greater in MDR than in wild type cells. The present study has
shown that VCR binding to MDR Ehrlich ascites tumour cell plasma membrane vesicles is inhibited 50%
most efficiently by quinidine (0.5 JLM) followed by verapamil (4.1 gtM) and trifluoperazine (23.2jAM). This is the
reverse order of the effect on whole cells where a ranking of efficiency in terms of enhancement of VCR
accumulation, inhibition of VCR efflux, DNA perturbation and modulation of resistance in a clonogenic
assay, was trifluoperazine > verapamil > > quinidine. The detergent Tween 80 inhibited VCR binding to
plasma membrane vesicles at 0.001% v/v which agreed with the level which modulated resistance and
increased VCR accumulation in whole cells. No effect was observed on daunorubicin binding to MDR plasma
membrane vesicles after incubation with either Tween 80 (up to 0.1% v/v) or verapamil (up to 25 tLM). We
conclude that the effect of a modulating drug in reversing resistance to VCR correlates with its ability to raise
intracellular VCR levels but not with its capability to inhibit VCR binding to the plasma membrane. Thus,
enhancement of VCR accumulation in MDR cells is hardly solely due to competition for a drug binding site
on P-glycoprotein. Furthermore, the lack of a demonstrable effect on daunorubicin binding to the plasma
membrane by modulators points to transport mechanisms which do not utilise specific drug binding to the
plasma membrane.
The multidrug resistance (MDR) phenotype is by now a well
described entity encompassing (1) cross-resistance between
vinca alkaloids, anthracyclines, epipodophyllotoxins and
actinomycin D, (2) emergence of a 170 kDa plasma mem-
brane glycoprotein called P-glycoprotein, (3) reduced intra-
cellular drug accumulation and (4) modulation or reversal of
resistance itself by verapamil (VER) and several other drugs
(recently reviewed by Bradley et al., 1988). Considerable
experimental evidence indicates a relationship between P-
glycoprotein and the decrease in intracellular drug concen-
tration in MDR cells, though the process whereby this occurs
is still unknown (Bradley et al., 1988). Since the observation
by Tsuruo et al. (1981) that VER was able to reverse the
MDR phenotype, the MDR modulating abilities of the cal-
modulin inhibitor trifluoperazine (TFP) (Ganapathi et al.,
1986) and the antiarrthymic drug quinidine (QDN) (Tsuruo
et al., 1984) have been the subject of major interest. As early
as 1972, the detergent Tween 80 was also shown to modulate
the MDR phenotype (Riehm & Biedler, 1972). The
mechanism by which these drugs modulate the MDR
phenotype is as yet unknown, although factors such as lipid
solubility at physiological pH, cationic charge and, to a lesser
extent, molar refractivity have been found to be of impor-
tance (Zamora et al., 1988).
It has been proposed that MDR modulators act by com-
petitive inhibition of drug binding to P-glycoprotein on the
plasma membrane and subsequent blocking of drug efflux
from the MDR cell (Gottesmann & Pastan, 1988). The pur-
pose of the present study was to determine whether inhibition
by the three classic MDR modulators VER, TFP and QDN
of drug binding to the MDR plasma membrane correlated
with their ability to (1) enhance intracellular drug accumu-
lation, (2) inhibit drug efflux and (3) modulate resistance per
se. The modulation of resistance was tested in two assays,
namely by clonogenic assay, as well as by increase of drug-
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induced cell-cycle perturbation measured by flow cytometric
analysis.
Materials and methods
Cell line
The wild type (EHR2) and daunorubicin (DNR) resistant
Ehrlich ascites tumour cell lines (EHR2/DNR + ) have
previously been described in detail (Dan0, 1971, 1972, 1973)
and EHR2/DNR + exhibits all of the characteristics of the
MDR phenotype. Cells were maintained as ascitic tumours as
described (Skovsgaard, 1978b).
Chemicals
G3H-DNR (1.9 Ci mmol ') was purchased from New
England Nuclear (USA) and G3H-vincristine (VCR)
(8.2 Ci mmol-' or 5.6 Ci mmol-' in different batches) from
Amersham (UK). Adenosine triphosphate (ATP), QDN, TFP
and Tween 80 were obtained from Sigma (USA) and VER
from Knoll (FRG).
Pldsma membrane vesicle preparation
Plasma membrane vesicles were prepared from EHR2/
DNR + as previously described (Sehested et al., 1989).
Briefly, after swelling and disruption of the cells by polytron-
ation in a hypotonic buffer, differential centrifugation (Bind-
slev & Wright, 1984) was followed by separation on a discon-
tinous Ficoll gradient under ultracentrifugation (Spitzer et
al., 1983). Plasma membranes, which were enriched >20-fold
over homogenate, were stored at - 80°C till use.
Determination ofdrug inhibition in plasma membrane vesicles
The rapid filtration technique for measurement of 3H-DNR
and 3H-VCR binding to plasma membrane vesicles was used
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(Bindslev & Wright, 1984; Sehested et al., 1989). Experiments
were performed with either simultaneous incubation of drug
tracer with a modulator or with 30 min preincubation at 4°C
for each modulator before incubation with drug tracer. All
experiments were done at final concentrations of 3.3 mM
ATP and 3.3 mM MgCI2 and were always performed at 37°C
for 10 min. 3H-VCR concentrations were in the 130-150 nM
and 3H-DNR concentrations in the 0.4-0.6 ,UM range. Inhibi-
tion experiments were performed at least three times.
Influence ofmodulators on VCR accumulation and efflux
inhibition in whole cells
Determination of 3H-VCR accumulation in whole cells was
performed as previously described (Skovsgaard, 1978b). The
effect of the modulators QDN, VER and TFP as well as the
detergent Tween 80 were measured after 60 min simultaneous
incubation at 37°C. Controls were medium with 10 mM
glucose, i.e. medium with energy, and energy depleted
medium containing 10 mM sodium azide without glucose
(Skovsgaard, 1978b). For determination of VCR efflux
inhibition, cells were first loaded with VCR by incubation in
medium containing 10 mM sodium azide and no glucose. At
30 min either 10 mM glucose alone, or 10 mM glucose +
10 LM modulator was added and the effect of modulator
compared with the two curves representing lack or presence
of energy respectively.
Clonogenic assay
The soft agar clonogenic assay system was as previously
described (Roed et al., 1987a, b). Briefly, 100 plA ascites
tumour cells were transferred to 10 ml medium (RPMI 1640
+ 10% fetal calf serum). The suspension was centrifuged at
150g for 5 min and the pellet resuspended in 10 ml medium.
The single cell suspension was exposed to increasing doses of
either VCR alone or VCR plus modulator in continuous
incubation for 3 weeks.
Hereafter colonies were counted using a dissecting micro-
scope, and surviving fractions were calculated by dividing the
number of colonies on the treated plates with the number of
colonies on the untreated control plates. The number of cells
plated was adjusted to obtain approximately 2,000 colonies
in the control dishes. Each experiment was done with three
agar plates per dosage, and repeated twice.
Determination of VCR induced cell cycle perturbations byflow
cytometric DNA analysis
Cell suspensions of I x 106 cells in 10 ml medium were
exposed to increasing doses of either VCR alone or VCR
plus modulator for 24 h in culture flasks. After centrifugation
at 150 g for 5 min, the cells were suspended in citrate buffer,
frozen on ethanol with dry ice, and stored at - 80°C until
analysis (Vindel0v et al., 1983a). The samples were stained
with propidium iodide (Vindel0v et al., 1983b) and analysed
in a FACS III flow-cytometer (Becton-Dickinson). The
percentage of cells in each cell cycle phase was determined by
statistical analysis of the DNA distribution (Christensen et
al., 1978).
Results
Influence ofMDR modulators on drug binding to plasma
membrane vesicles
In Figure 1 is shown the inhibition of 3H-VCR binding to
plasma membrane vesicles by the various modulators. No
difference was observed between preincubation or simul-
taneous incubation with these modulators. QDN was the
most potent inhibitor and TFP the weakest. When Tween 80
was preincubated with plasma membrane vesicles for 30 min
at 4°C, inhibition of 3H-VCR binding occurred dramatically
at 0.001% v/v with hardly any further inhibition up to 0.1%
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Figure 1 Inhibition of 3H-VCR binding to plasma membrane
vesicles from EHR2/DNR + cells by MDR modulators. VCR
concentration in medium was 130 nm and VCR binding to
plasma membrane vesicles at 100% was approximately
5 pmol mg-' protein. ATP and MgCI2 concentration was 3.3 mM.
Experiments were performed for 10 min at 37°C. Bars represent
2s.d. 0 *, QDN; A A, VER; * U*, TFP.
v/v (Figure 2). However, when Tween80 was incubated
simultaneously with 3H-VCR, no effect was observed up to
0.1% v/v (Figure 2).
In contrast to 3H-VCR which showed an ATP-enhanced
binding in MDR compared to sensitive cell plasma mem-
branes, 3H-DNR binding to sensitive and MDR plasma
membrane vesicles was similar and showed no time or
temperature dependency (Sehested et al., 1989). Neither
simultaneous nor preincubation with VER up to 25 ltM or
Tween 80 up to 0.1% v/v had any effect on 3H-DNR binding
to MDR plasma membrane vesicles (not shown).
Modulation of VCR accumulation andefflux in whole cells
Increase of intracellular VCR levels in the MDR cells by
QDN, VER, TFP and Tween 80 is shown in Figure 3. TFP
was the most efficient followed by VER, and QDN the least
efficient of the three modulators in raising intracellular VCR
levels, the difference being most noticeable at the 5 JLM level.
This agrees with the findings shown in Figure 4 where TFP
and VER at 10 iM both effectively inhibit VCR efflux while
QDN does so to a lesser extent. Tween 80 also raised VCR
accumulation at 0.001% v/v, the same level as for inhibition
of VCR binding to plasma membrane vesicles (Figure 2).
Modulation of VCR resistance
Modulation of resistance in the clonogenic assay system to
VCR by QDN, VER and TFP is shown in Figure 5. At the
5 gM level TFP and VER show reversal of resistance while
C :a
C
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Figure 2 Inhibition of 3H-VCR binding to plasma membrane
vesicles from EHR2/DNR + cells after preincubation for 30 min
at 4°C and simultaneous incubation with the detergent Tween 80.
Bars represent 2 s.d. 0 0, preincubation; 0 0, simul-
taneous incubation.
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Figure 3 Effect on VCR levels in whole EHR2/DNR + cells
after simultaneous incubation with MDR modulators. VCR
levels in EHR2 cells in medium containing 10 mm glucose is
included for comparison. VCR concentration was 1.0 gLM. Except
for A all media included 10 mm glucose. Bars represent 2 s.d. S,
wild type EHR2 cells with 10 mm glucose; G, EHR2/DNR +
cells, control without modulator with 10 mm glucose; A, EHR2/
DNR + cells, control without modulator with 10 mm sodium
azide and without glucose, 5, 10, 25 = EHR2/DNR + cells,
medium contained 5juM, 10 pM and 25 pM modulator respec-
tively. 10-4, 10-3 = EHR2/DNR + cells, medium contained
Tween 80 at 0.0001% v/v and 0.001% v/v respectively.
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Figure 4 Inhibition of 3H-VCR efflux from EHR2/DNR + cells
by modulators. Cells were first incubated in 1O mM sodium azide
without glucose (0 O). At 30 min 10 mM glucose
(0 *), 10mM glucose + 10 yM VER (V V), 10mM
glucose + 10 lM TFP (U * *) or 10 mM glucose + 10 gM
QDN (0 ) was added. -~--------------.---.----.I
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Figure 5 Modulation of resistance to VCR in EHR2/DNR + cells by continuous incubation with TFP, VER and QDN. The
curves end when less than 0.1% survived at next tested concentration. Bars represent 2 s.e.m. Note that VER is the only modulator
to be atoxic at 5 tsM. VCR alone; .......... VCR + 5 #M QDN; ----, VCR + 5 tsM VER; -, VCR +
5 tM TFP; --, VCR + 2.5JM TFP.
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QDN demonstrates an additive toxic effect. VER was the
only modulator which was without any toxicity itself at 5 JAM,
while TFP had a greater than 50% decrease in survival at
this level. Because of this TFP toxicity, a new level of 2.5 JAM
was tested but this resulted in greater toxicity and lower
effect than VER at 5 JIM. Thus VER was the best modulator
when toxicity was taken into account.
Tween 80 modulates resistance to VCR from 0.001% v/v
(Figure 6), which is the same level necessary for inhibition of
VCR binding to plasma membrane vesicles (Figure 2) and
for increasing cellular VCR levels (Figure 3).
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Modulation of VCR induced cell cycleperturbations
The effect of VCR on the DNA distribution is shown in
Figure 7. Only the highest tested doses of VCR alone result
in a low yield of G2M accumulation/polyploidisation when
no modulators are used. None of the modulators perturbed
the DNA distributions when used alone at 5 JLM (not shown).
Figure 7 clearly demonstrates that VER and TFP are con-
siderably more potent than QDN at enhancing the VDR
induced cell cycle perturbation, although QDN does have an
effect.
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Figure 6 Modulation of resistance to VCR in EHR2/DNR + cells by continuous
2 s.e.m. , VCR alone; , VCR + 0.0001% v/v Tween 80; -
- - -, VCR + 0.01% v/v Tween 80.
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Figure 7 The DNA perturbing effect in EHR2/DNR + cells of 24 h incubation with VCR alone and VCR together with 5 A4M
modulator. The VCR effect is depicted as percent polyploidy, i.e. the percentage of cells belonging to a population with GI and 4N
and G2M at 8N. 0, VCR alone 0 0, VCR + 5JM QDN; * 0, VCR + 5 pM TFP; A A, VCR + 5 lM
VER.
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Discussion
MDR cells are characterised by decreased intracellular drug
concentrations, considered to be partly due to an increased
energy dependent drug efflux (Skovsgaard, 1978a). Although
the mechanism of the reduced drug accumulation is still
unknown, considerable evidence points to a link with P-
glycoprotein (Bradley et al., 1988). While it has been
advocated that P-glycoprotein acts as an outward directed
pump per se for the diverse drugs in the MDR family
(Gottesman & Pastan, 1988), other possibilities exist, such as
efflux via a carrier analagous to the haemolysin transporter
in E. coli, with which P-glycoprotein shares homologous
sequences (Gerlach et al., 1986), or via an exocytotic process
(Beck, 1987; Klohs & Steinkampf, 1988; Sehested et al.,
1987). Drugs which modulate MDR are thought to do so by
inhibiting this efflux mechanism, leading to raised intracel-
lular drug levels. By investigating the action of modulators it
might therefore be possible to learn more about the efflux
mechanism.
We (Sehested et al., 1989) and others (Horio et al., 1988;
Naito et al., 1988) have demonstrated an increased ATP
enhanced binding of vinca alkaloids to plasma membrane
vesicles from MDR cells compared to sensitive cells. It is
noteworthy that both QDN and VER are potent inhibitors
of this vinca alkaloid binding, with 50% inhibitions of <
5 JAM in all three studies. Furthermore, both we and Naito et
al. (1988) found that TFP was much less efficient at
inhibiting VCR binding with a 50% inhibition at 20 JAM TFP
reported by Naito et al. (1988) and 23 JAM TFP in the present
study (Figure 1). Recently, Naito et al. (1989) have shown
the same QDN > VER > TFP sequence in potency of
competitive inhibition of VCR binding to plasma membrane
vesicles from human MDR K562 cells as found in the present
study, indicating that this is a common sequence. We were
therefore surprised to find that TFP was superior to both
VER and QDN in raising VCR accumulation in whole cells
(Figure 3). These results of enhancement of VCR accumula-
tion agree with both the ability to inhibit VCR efflux (Figure
4) and to reverse resistance itself in the clonogenic assay
(Figure 5), where TFP was most efficient on a molar basis
but VER the best modulator when toxicity of the modulator
itself was taken into consideration. The lack of any
modulating effect by QDN at 5 JM would indicate that its
enhancement of VCR accumulation as shown in Figure 3 is
insufficient at this level to influence resistance in a clonogenic
assay system. However, when we used cell cycle perturbation
as an assay for measuring modulator enhancement of VCR
effect we were able to detect an effect of QDN which was
considerably less than that of both VER and TFP (Figure 7).
That VCR is one of the few drugs which by itself can cause
polyploidisation was first observed by Alabaster and Cassidy
(1978), and the lack of effect of TFP alone agrees with results
by Ganapathi et al. (1986).
Studies with photoaffinity analogues of both vinca
alkaloids and VER have demonstrated labelling of P-
glycoprotein (Cornwell et al., 1986; Safa et al., 1986; Safa,
1988), and it is reasonable to assume that the ATP enhanced
binding of VCR to MDR plasma membrane vesicles is due
to binding to P-glycoprotein. It is interesting that while QDN
is reported to inhibit this photoaffinity labelling with 50%
inhibition <10JAM, TFP does so poorly (50% inhibition
>20 LM) (Akiyama et al., 1988), results which would explain
the relatively poor inhibition of VCR binding to plasma
membrane vesicles by TFP in the present study and reported
by Naito et al. (1988). We can therefore conclude that the
ability of TFP, VER and QDN to reverse resistance to VCR
correlates with their capacity to increase intracellular VCR
levels but not with their power to inhibit VCR binding to
plasma membrane vesicles. Thus, it is not likely that inhibi-
tion of efflux of VCR from MDR cells is solely due to
competitive inhibition by the various modulators of a specific
drug binding site. This is supported by recent results from
Klohs et al. (1989) who, by utilising the technique of com-
petitive drug inhibition of azidopine labelling of P-
glycoprotein also found a lack of correlation between the
ability of a drug to bind to P-glycoprotein and its capacity to
overcome MDR.
The ability of the non-ionic detergent Tween 80 to
modulate the MDR phenotype was described as early as
1972 (Riehm & Biedler, 1972), and has since been confirmed
in several studies (Klohs & Steinkamf, 1988; Seeber et al.,
1982). The effect of Tween 80 on inhibition of VCR binding
to plasma membrane vesicles (Figure 2) differed from that of
the other modulators in that preincubation was necessary.
This would indicate that the influence on the VCR binding
site, i.e. P-glycoprotein, was secondary to other changes,
presumably in the lipid bilayer. However, a good correlation
was seen between inhibition of VCR binding to plasma mem-
brane vesicles (Figure 2), raising of intracellular VCR levels
(Figure 3) and modulation of resistance (Figure 6) as
Tween 80 showed a dramatic effect at 0.001% v/v in all three
systems. This Tween 80 concentration may well be of clinical
interest as the drug VP-16 (Vepesid, Bristol-Myers, USA),
which belongs to the MDR family (Seeber et al., 1982), is
delivered in a vehicle containing Tween 80 in such an amount
that a single infusion of 200 mg VP-16, a normal dose for a
70 kg patient, will contain 0.73 ml Tween 80 leading to
0.001% v/v.
Neither VER nor Tween 80 had any effect on DNR bin-
ding to plasma membrane vesicles, even after preincubation
with the modulator. This is in spite of that VER at 25 ILM
has been shown to increase intracellular DNR in EHR2/
DNR + to levels approaching those found in sensitive EHR2
cells (Friche et al., 1987), and also that Tween 80 at 0.001%
v/v significantly enhanced DNR accumulation in EHR2/
DNR + (T. Skovsgaard, unpublished results). This is in
agreement with our previous results (Sehested et al., 1989)
which failed to demonstrate any specific DNR binding site
on the EHR2/DNR + plasma membrane. This lack of
specificity for DNR together with the described poor correla-
tion between modulator inhibition of binding of VCR to
P-glycoprotein on one hand and their ability to raise intracel-
lular VCR levels and to reverse resistance to VCR on the
other hand are difficult to reconcile with the notion that
modulators increase drug accumulation simply by blocking a
pump site on the P-glycoprotein molecule as has been pro-
posed.
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